In 1997, the Eastern Mediterranean Region (EMR) of the World Health Organization adopted a resolution to eliminate measles by 2010. Of the 23 EMR member countries, 18 are polio-free and are building on this success to eliminate measles. The 5 countries where polio remains endemic are prioritizing polio eradication and working to improve measles control. Measles incidence has been reduced from 193/100,000 in 1981 to 6.8/ 100,000 in 2001. Supplemental vaccination campaigns for measles have been conducted since 1994 in 14 of the 18 polio-free countries. More than 50 million children have been immunized in these supplemental activities. However, in Afghanistan, Sudan, Somalia, Djibouti, and Pakistan, where 34% of the EMR population live, routine vaccination coverage for measles remains below 60% and measles deaths are estimated at 81,000 annually among children !5 years old. Significant resources must be allocated to these last 5 countries to achieve regional measles elimination by 2010.
The Eastern Mediterranean Region (EMR) Office of the World Health Organization (WHO) addresses the health of countries in the eastern Mediterranean, northern Africa, Arab Gulf states, Middle East, and Asia. Health and socioeconomic indicators vary greatly across countries because the region includes some of the world's wealthiest countries and some of the least developed that are torn by war and civil strife [1] .
In October 1997, the EMR member countries adopted a resolution for elimination of measles from the region by 2010 [2] . The resolution endorsed the following four strategies to achieve this goal: achieving and maintaining routine measles vaccination coverage 195% among children aged 1 year; conducting a onetime, nationwide, mass immunization campaign or catch-up campaign targeting all children (usually those aged 9 months-15 years), regardless of history of measles disease or vaccination; conducting periodic national follow-up campaigns every 3-5 years, targeting all children born since the last campaign (usually those aged 9 months-4 years), or achieving 195% routine coverage with a second routine dose of measles vaccine; and strengthening measles surveillance and laboratory confirmation of cases [3] . Based on the polio eradication status and level of measles control, member countries were divided into two groups: elimination and control [4, 5] .
Countries in the elimination group are known to be polio-free by high-quality surveillance and have a rate of acute flaccid paralysis (AFP) 11 per 100,000 children aged !15 years, and adequate stool sample collection. The inclusion of a country in the elimination group depends on its ability to maintain polio eradication and to implement measles elimination activities at the same time. Elimination group countries include Bahrain, Cyprus, Egypt, Iran, Iraq, Jordan, Kuwait, Libyan Arab Jamahiriya, Lebanon, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates (UAE), Yemen, and the Palestine National Authority. Nearly 66% of the region's population, estimated at 526 million inhabitants, live in countries in the elimination group.
In measles control group countries (Afghanistan, Djibouti, Pakistan, Somalia, and Sudan), polio is endemic and/or AFP surveillance is not adequate to demonstrate interruption of poliovirus circulation. In these countries, measles control activities are being accelerated to reduce measles morbidity and mortality as a step toward elimination. Measles control activities in these countries include the identification of groups at high risk for measles transmission so that these can be targeted for supplementary immunization activities, the integration of measles surveillance with AFP surveillance, and laboratory testing to confirm outbreaks [4] . Here we summarize the progress toward measles elimination and control in these two groups of countries and the challenges that remain to achieve measles by 2010.
METHODS

Measles elimination countries.
The expanded program on immunization started in 1980 in the majority of EMR countries [6] . The program was funded initially by UNICEF and later by individual governments. New vaccines have been gradually added to national vaccination schedules and there are ongoing efforts to modernize cold chain equipment.
A second dose of measles-containing vaccine was incorporated into the routine childhood vaccination schedule by 16 of the 18 elimination countries (exceptions are Morocco and Yemen) at ages ranging from 15 months to 6 years. Both doses are administered as single-antigen measles vaccine in Iran and Tunisia. In Egypt, Iraq, Jordan, Lebanon, Libyan Arab Jamahiriya, Oman, the Palestine National Authority, the United Nations Relief and Works Agency (UNRWA), Syria, and the UAE, the first dose is single-antigen measles vaccine and the second dose is measles-mumps-rubella (MMR) vaccine (table  1) . Economic considerations are being assessed in the remaining countries administering monovalent measles vaccine to incorporate MMR into the routine vaccination program [7] .
The proportion of children immunized with a measles-containing vaccine by age 1 year is routinely measured based on the reported number of doses administered and available population estimates. In countries where the first dose of measles vaccine is administered after age 12 months (Kuwait, Bahrain, Oman, Qatar, Saudi Arabia, Tunisia, and Cyprus), coverage is estimated for children aged 12-23 months.
Vaccine safety has been emphasized with the growth of the program, and biosafety procedures are carefully monitored during vaccination campaigns. Although not all countries have access to auto-disable (AD) syringes and safety boxes, regular training of staff, dissemination of clear guidelines, and direct supervision in the field have resulted in improved quality of vaccination services (WHO EMR, Cairo, unpublished data).
Elimination activities began in 1994 with catch-up campaigns in Oman and Kuwait and other countries soon followed ( Measles control countries. Measles vaccine is administered in these countries at age 9 months [8] . Routine vaccination coverage has been historically low due to war and political instability. Due to high measles morbidity and mortality, it has been necessary to implement mass campaigns in these countries during the last 6 years. A recent study in Afghanistan found that measles was a leading cause of death among children, accounting for more than 15% of all deaths in children !5 years old [9] . Measles surveillance in this group of countries is based on passive reporting of cases.
RESULTS
Measles Elimination Countries
Vaccination coverage. Vaccination coverage started to increase after a large regional measles outbreak in 1983 (1250,000 reported cases). Vaccination coverage for measles in children by age 1 year increased from 44% in 1984 to 80% in 1989. Since 1996, measles vaccination coverage with the first dose in the countries in the elimination group has increased to 190%. The highest coverage was 94% in 2000 ( figure 1 ). Of the 16 countries that routinely administer two doses of vaccine, 14 reported coverage to the WHO; in 2001, routine second-dose coverage was 92% (range, 77%-100%). Countries with low incidence of measles (Oman, Tunisia, and Kuwait) have very high routine second-dose coverage.
Disease surveillance. After the introduction of vaccination against measles in the early 1980s and the subsequent gradual increase in coverage, the number of cases decreased from an incidence of 193/100,000 in 1981 to 30/100,000 in 1989. In the 1990s there were two peaks in the number of reported cases in 1992 and in 1998. Incidence was 29/100,000 in both years. The lowest measles incidence rate reported by these countries was 5.4/100,000 in 1996. In 1998, 78,425 (97%) of the total (table 2) . Measles vaccine as a single antigen or combined with rubella vaccine has been utilized for these mass campaigns. Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Tunisia, and UAE conducted catch-up campaign for children aged 1-15 years. However, some countries included children as young as 9 months. In other countries, due to documented high vaccination coverage with the routine program during the last 5 years, the age groups targeted in the catch-up campaign excluded children !5 years old. In Bahrain, Kuwait, Oman, Saudi Arabia, and UAE, the age group was extended to 18 years (table  2) . The reported campaign coverage was 68%-115% (the last probably was due to underestimation of the total population in the target group). Countries that reported high vaccination coverage during their catch-up campaigns (190%) have observed a marked decline in the number of cases in recent years. The WHO recommends that follow-up campaigns be considered if the number of susceptible persons is equal to one age cohort. To date only Kuwait and Tunisia have implemented follow-up campaigns in this region. Kuwait conducted a catchup campaign in 1994 and a follow-up campaign in 1998 and reported coverage of 93%. In Kuwait, reported measles cases decreased to record-low numbers in 1997 but increased due to an outbreak in 1998, because not all required age cohorts were included in the follow-up campaign. In 2001, only 10 cases (incidence, 0.6/100,000 population) were reported in Kuwait. Tunisia also implemented a follow-up campaign in 2001, achieving coverage of 94%.
One of the largest nationwide campaigns in the region was conducted in Egypt in 2000-2001 and targeted 17.2 million children aged 6-11 years and achieving a reported coverage of 98%. Lebanon and Saudi Arabia conducted catch-up campaigns in 2000 for children aged 1-14 and 6-13 years, respectively. Reported coverage was 97% in Saudi Arabia and 73% in Lebanon.
Egypt, Iraq, and Yemen have conducted the initial phase of Morocco planned a campaign in 1998 that was postponed because of a lack of resources. In 1999, Morocco experienced a large epidemic of measles in the same age groups targeted by the planned campaign. Despite the high routine coverage achieved with a single dose of measles vaccine at age 9 months, epidemics continue in Morocco every 2-3 years.
Laboratories. There are two regional reference laboratories, one in Oman and one in Tunisia, and all countries in the elimination group have nominated a national laboratory for measles that has demonstrated good performance in proficiency testing. Two countries recently isolated measles virus: Morocco isolated the genotype C2 that is also circulating in Western Europe and Tunisia isolated the genotype B3 commonly found in West and Central Africa. An example of the improving performance of EMR measles laboratories is observed in Tunisia. From 1999 to 2001, Tunisia improved the number of measles cases investigated with laboratory analysis. In 1999, of 441 suspected cases, 331 (75%) had a serum sample collected for diagnosis; this proportion increased in 2000 to 363 (82%) of 442 suspected cases. In 2001 the number of suspected cases increased to 1241; of these, 1023 (82%) had a serum sample collected for analysis. Other countries such as Oman, Iran, Cyprus, and Syria also have improved the quality of measles surveillance by collecting serum samples; however, the results of these investigations are not reported regularly to the EMR.
Effect of elimination activities in Oman.
Oman has achieved and maintained high routine measles immunization coverage (198%) due to a system of defaulter tracking based on birth registrations, frequent and regular supervision, and scheduled outreach visits. As a result of high coverage with the first dose, the introduction of a routine second dose in 1994, and a successful catch-up campaign in 1994, measles incidence has been reduced to very low levels. Endemic measles transmission has been interrupted, and only cases imported from outside the country have been registered during the last 5 years. Oman has implemented case-based surveillance with laboratory confirmation.
Measles Control Countries
Vaccination coverage. Routine vaccination coverage in the control countries remained below 50% in the 1980s. In 1990, vaccination coverage increased to 54%, dropped to 52% in 1995, and rose to 57% in 2001.
Campaigns.
To prevent the estimated 35,000 measles deaths annually in Afghanistan, a nationwide measles mortality Vitamin A supplementation has been an essential component of measles mortality reduction and is implemented several times every year, usually concurrent with national polio immunization days. Coverage with Vitamin A during these campaigns is 34%-94%. The largest campaign of this kind was in Pakistan where 125 million children received vitamin A supplementation in 1999.
Disease surveillance. Data show a decrease in measles cases from 129,454 (incidence, 101/100,000 population) in 1981 to 20,623 (incidence, 9/100,000 population) in 2001. However, due to incompleteness of reporting, this represents a small fraction of the true number of cases [10] . WHO estimates that 81,000 measles deaths occur annually in the EMR, most in Afghanistan, Djibouti, Somalia, Sudan, and Pakistan [11] . These deaths represent about one-fifth of all deaths due to infectious diseases in the region in 1 year. Integration of polio and measles surveillance has had good results in Afghanistan. Surveillance officers have been trained to collect information on measles and to document the epidemiologic situation, including measles outbreaks. The system successfully documented a large measles outbreak in Afghanistan in 2000 and 2001.
DISCUSSION
Control of vaccine-preventable diseases, including measles elimination, is a high priority in the EMR. Gradually more countries are conducting high-quality immunization activities (both routine activities and vaccination campaigns) and have improved surveillance, which is essential if the region is to achieve measles elimination by 2010.
The high routine measles vaccination coverage achieved in the elimination countries was due to the following strategies: setting targets to be accomplished at the health clinic; vaccinating children at any visit to the health center; giving parents written notification of vaccinations due; identifying and tracking children who have missed a scheduled immunization (including home visits); intensively educating the community and providers; giving supervision and feedback to immunization providers; and expanding outreach programs [6] . Countries should monitor and report coverage at the lowest administrative level on a regular basis. Supervision and feedback are necessary to ensure timely corrective measures in areas with low coverage. Estimation of age-specific susceptibility based on vaccine coverage is necessary to plan supplemental vaccination activities.
Maintaining high population immunity can interrupt endemic transmission of measles virus [12] but accumulation of susceptible populations represents the greatest risk to measles elimination [13] [14] [15] . Countries that conducted high quality catch-up campaigns have had a marked decrease in cases. In Bahrain, Kuwait, Oman, and Tunisia, measles cases reported during 2001 were linked to importations from endemic countries. In contrast, countries that have yet to conduct or complete an initial campaign (e.g., Morocco, Iran, Egypt, and Libya) continue to have large periodic epidemics.
Enhancement of case-based surveillance with detailed epidemiologic investigation from suspected cases, and laboratory confirmation of diagnosis with virus isolation from all chains of measles transmission is required to determine and monitor interruption of indigenous transmission of measles and to evaluate the impact of the elimination activities [16] [17] [18] . Identification of the indigenous genotypes should be a priority among countries reporting few measles cases to document interruption of indigenous transmission [17] . Although surveillance has improved and suspected cases are tested in EMR measles elimination countries, the majority of cases are still confirmed clinically. Monitoring of surveillance indicators should be strengthened to validate the quality of information. These surveillance indicators should include the number and proportion of reporting units on a weekly basis, the number and proportion of suspected cases with an adequate blood sample, and the number of suspected cases confirmed and discarded by IgM tests.
Supplemental immunization activities and the routine vaccination program must ensure that all countries implement vaccine safety standards. This is of concern in the EMR because worldwide it is estimated that one of three injections is not delivered safely [19] . Safety boxes and AD syringes must be available at the time of vaccination, and disposal procedures of safety boxes must be ensured. These actions will be followed only if training for vaccinators is repeated regularly and extensive supervision is implemented in the field. Countries in the measles control group must ensure that trained staff is available before implementing national campaigns.
In the EMR, countries in the measles elimination group are on course to interrupt indigenous measles transmission by 2010. Yet challenges remain to be addressed. These include securing resources for countries planning initial catch-up and follow-up campaigns; maintaining high routine vaccination coverage for scheduled doses and during vaccination campaigns; improving surveillance and performance measures by using surveillance indicators; having laboratory confirmation of all cases; reporting uncomplicated cases by the public and private sector; encouraging active surveillance, because the apparent absence of cases may weaken measles surveillance, and outbreaks may pass undetected; and periodically assessing the population susceptible to measles to establish age groups and timeliness for follow-up campaigns (if coverage and disease surveillance alone are inadequate, serologic surveys may be needed).
In contrast, in the control countries measles is a leading cause of morbidity and mortality in children !5 years old. Although progress on measles elimination has been significant at the regional level, nearly a third of the EMR population lives in countries with prevalent measles morbidity and mortality. In these countries routine vaccination services are at the same level as a decade ago. The low level of immunity allows endemic virus circulation and regular outbreaks. Quality routine vaccination services delivery will be difficult to develop and sustain in the short term and supplemental immunization activities are needed to increase immunity of the population.
Epidemiologic surveillance is weak and measles is largely underreported in Afghanistan, Djibouti, Somalia, Sudan, and Pakistan. To improve disease surveillance, training must be conducted and oriented to integrate surveillance with other vaccine-preventable diseases. Surveillance indicators must be monitored to measure data quality. There should be laboratory confirmation of the first 5 cases during outbreaks. Data need to be carefully analyzed to establish populations at risk, and vaccination coverage information should be combined with available epidemiologic information to plan future activities.
At the regional level, the main challenges for eliminating measles are the political stability of some EMR states and securing the necessary political commitment and financial resources for implementation of campaigns and strengthening of routine immunization (e.g., Afghanistan, Somalia, and Sudan). Millions of refugees move across boundaries yearly, and health conditions are among the worst humankind has experienced [20, 21] . Infectious diseases are worsened by malnutrition and lack of vitamin A, contributing to elevated infant mortality rate.
Securing financial resources also requires strong political support to guarantee that resources are available when countries are ready to implement campaigns. To delay implementation of measles elimination activities may affect the entire vaccination program in the region. To eliminate measles, early establishment of goals by country will be a definitive factor for success. Measles campaigns should not interfere with polio eradication in endemic countries, and the groundwork laid by polio national immunization days should be the basis of a future program to improve delivery of all vaccines including measles. In the meantime, adequate disease surveillance must be developed to monitor for and document the epidemiology of measles in order to adequately plan the vaccination campaigns for all susceptible cohorts, interrupt endemic circulation of measles, and achieve regional elimination.
